Overview

Study of NPF-08 in Patients Who Receive Colonoscopy

Status:
Completed
Trial end date:
2019-06-19
Target enrollment:
Participant gender:
Summary
To study non-inferiority of intestinal cleansing effect in both NPF-08 1-day treatment group and NPF-08 2-day split dose group to the cleansing effect in Moviprep® 1-day treatment group, for the subjects who will receive endoscopy large bowel. If the non-inferiority will be validated, superiority of intestinal cleansing effect in both groups of NPF-08 will be studied. Furthermore, for the assessment of safety of NPF-08, the adverse events and adverse drug reactions observed after the administration to post-examination period will be studied, compared to those at Moviprep® 1-day treatment group.
Phase:
Phase 3
Details
Lead Sponsor:
Nihon Pharmaceutical Co., Ltd